The Study Aims to Measure the Metabolome in Melanoma Patients Using NMR Spectroscopy and Gas Chromatography and to Analyse Differences Depending on the Course of the Disease.

Recruiting

• Conditions: Melanoma of Skin

• Registration Number: NCT06765850
• Lead Sponsor: Technische Universität Dresden

Brief Summary

Prospective, single-centre study with the central question of how the metabolome from blood samples, different body fluids and tissues between patients patients with malignant melanoma in different tumour tumour stages and healthy patients and whether this is suitable for early detection of initial diagnosis, recurrence or stage shift at an early stage.

The biosamples are collected in the BioBank Dresden and used for the NMR and LC-MS analyses described here. It is planned to use the biosamples for further analyses.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-07-04
• Study First Submitted: 2024-12-17
• Status Verified: 2025-01
• Study First Submitted QC: 2025-01-03
• Last Update Submitted: 2025-01-03
• Study First Posted: 2025-01-09
• Last Update Posted: 2025-01-09
• Primary Completion: 2026-12
• Study Completion: 2027-06

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 3000

Inclusion Criteria

• Current or past history of melanoma
• Ongoing therapy or tumour aftercare at the Skin Cancer Centre at Dresden University Hospital

Exclusion Criteria

• Refusal to participate in the study
• Lack of capacity to consent

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Differences in metabolite concentrations	through study completion, an average of 3 years	Metabolite concentrations are measured by NMR spectroscopy and gas chromatography and compared between different subgroups.

Trial Locations

Locations (1)

University Hospital Carl Gustav Carus; 🇩🇪 Dresden, Saxony, Germany